Stent delivery systems with a reinforced deployment sheath

Information

  • Patent Grant
  • 11351048
  • Patent Number
    11,351,048
  • Date Filed
    Tuesday, November 15, 2016
    8 years ago
  • Date Issued
    Tuesday, June 7, 2022
    2 years ago
Abstract
Stent delivery systems and methods for making and using the same are disclosed. An example stent delivery system may include an inner member. A deployment sheath may be disposed about the inner member. A stent may be disposed between the inner member and the deployment sheath. The deployment sheath may include a translucent reinforcing member that allows for visualization of the stent during stent deployment.
Description
TECHNICAL FIELD

The present invention pertains to medical devices and methods for making and using medical devices. More particularly, the present invention pertains to stent delivery systems.


BACKGROUND

A wide variety of intracorporeal medical devices have been developed for medical use, for example, intravascular use. Some of these devices include stent delivery systems. These devices are manufactured by any one of a variety of different manufacturing methods and may be used according to any one of a variety of methods. Of the known stent delivery devices and methods for making and using the same, each has certain advantages and disadvantages. There is an ongoing need to provide alternative stent delivery devices as well as alternative methods for making and using stent delivery devices.


BRIEF SUMMARY

The disclosure provides design, material, manufacturing method, and use alternatives for stent delivery systems. An example stent delivery system is disclosed. The stent delivery system comprises:


an inner member;


a deployment sheath disposed about the inner member;


a stent disposed between the inner member and the deployment sheath; and


wherein the deployment sheath includes a translucent reinforcing member that allows for visualization of the stent during stent deployment.


Alternatively or additionally to any of the embodiments above, the stent includes a self-expanding stent.


Alternatively or additionally to any of the embodiments above, the translucent reinforcing member includes a braid.


Alternatively or additionally to any of the embodiments above, the translucent reinforcing member includes a coil.


Alternatively or additionally to any of the embodiments above, the translucent reinforcing member includes a polymer.


Alternatively or additionally to any of the embodiments above, the translucent reinforcing member includes polyetheretherketone.


Alternatively or additionally to any of the embodiments above, the deployment sheath has a length, and wherein the translucent reinforcing member extends along substantially the entire length of the deployment sheath.


Alternatively or additionally to any of the embodiments above, the deployment sheath has a proximal region and a distal region, and wherein the translucent reinforcing member extends along the distal region.


Alternatively or additionally to any of the embodiments above, the distal region has an enlarged outer diameter relative to the proximal region, an enlarged inner diameter relative to the proximal region, or both.


Alternatively or additionally to any of the embodiments above, the deployment sheath includes an inner liner and an outer layer, and wherein at least a portion of the translucent reinforcing member is disposed between the inner liner and the outer layer.


Alternatively or additionally to any of the embodiments above, the inner liner, the outer layer, or both are at least partially translucent.


Alternatively or additionally to any of the embodiments above, further comprising a handle coupled to the inner member and to the deployment sheath, the handle including an actuation member capable of shifting the longitudinal position of the deployment sheath relative to the inner member.


A method for manufacturing a stent delivery system is disclosed. The method comprises:


forming a deployment sheath, wherein forming the deployment sheath comprises:

    • positioning an inner liner along a mandrel,
    • disposing a translucent reinforcing member along the inner liner, and
    • disposing an outer layer along the translucent reinforcing member;


disposing an inner member within the deployment sheath; and


disposing a stent between the inner member and the deployment sheath.


Alternatively or additionally to any of the embodiments above, the translucent reinforcing member includes polyetheretherketone.


Alternatively or additionally to any of the embodiments above, the inner liner, the outer layer, or both are at least partially translucent.


A stent delivery system for use along a biliary tract, an enteral tract, or an airway is disclosed. The stent delivery system comprises:


an inner member;


a deployment sheath disposed about the inner member;


a self-expanding stent disposed between the inner member and the deployment sheath; and


wherein the deployment sheath includes an inner liner, an outer layer, and a translucent braided reinforcing member disposed at least partially between the inner liner and the outer layer, the translucent braided reinforcing member being capable of allowing for visualization of the self-expanding stent during stent deployment.


Alternatively or additionally to any of the embodiments above, the translucent braided reinforcing member includes a polymer.


Alternatively or additionally to any of the embodiments above, the translucent braided reinforcing member includes polyetheretherketone.


Alternatively or additionally to any of the embodiments above, the deployment sheath has a proximal region and a distal region, and wherein the translucent braided reinforcing member extends along at least the distal region.


Alternatively or additionally to any of the embodiments above, the distal region has an enlarged outer diameter relative to the proximal region, an enlarged inner diameter relative to the proximal region, or both.


The above summary of some embodiments is not intended to describe each disclosed embodiment or every implementation of the present disclosure. The Figures, and Detailed Description, which follow, more particularly exemplify these embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:



FIG. 1 is a partial cross-sectional side view of an example stent delivery system;



FIG. 2 is a side view of a portion of an example stent delivery system;



FIG. 3 is a side view of a portion of an example stent delivery system;



FIG. 4 is a side view of a portion of an example stent delivery system;



FIG. 5 is a side view of a portion of an example stent delivery system;



FIG. 6 is a cross-sectional view taken through line 6-6 in FIG. 5;



FIG. 7 is a schematic illustration of a portion of an example stent delivery system;



FIG. 8 is a schematic illustration of a portion of an example stent delivery system; and



FIG. 9 is a partial cross-sectional side view of a portion of the example stent delivery system.





While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention.


DETAILED DESCRIPTION

For the following defined terms, these definitions shall be applied, unless a different definition is given in the claims or elsewhere in this specification.


All numeric values are herein assumed to be modified by the term “about,” whether or not explicitly indicated. The term “about” generally refers to a range of numbers that one of skill in the art would consider equivalent to the recited value (i.e., having the same function or result). In many instances, the terms “about” may include numbers that are rounded to the nearest significant figure.


The recitation of numerical ranges by endpoints includes all numbers within that range (e.g. 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, and 5).


As used in this specification and the appended claims, the singular forms “a”, “an”, and “the” include plural referents unless the content clearly dictates otherwise. As used in this specification and the appended claims, the term “or” is generally employed in its sense including “and/or” unless the content clearly dictates otherwise.


The following detailed description should be read with reference to the drawings in which similar elements in different drawings are numbered the same. The drawings, which are not necessarily to scale, depict illustrative embodiments and are not intended to limit the scope of the invention.



FIG. 1 illustrates an example stent delivery system 10. System 10 may include an elongate shaft 12 and a handle 14 coupled to shaft 12. In general, system 10 may be used to deliver a suitable stent, graft, endoprosthesis or the like to an area of interest within a body lumen of a patient. In some instances, the body lumen may be a blood vessel located near the heart (e.g., within or near a cardiac vessel), within a peripheral vessel, within a neurological vessel, or at any other suitable location. In other instances, the body lumen may be along the biliary tract, enteral tract, along an airway, or the like. Deployment of the stent may include the proximal retraction of a retraction sheath 16, which overlies the stent. Retraction of sheath 16 may include the actuation of an actuation member 18 generally disposed at handle 14. In the example illustrated in FIG. 1, actuation member 18 is a thumbwheel that can be rotated by a clinician in order to accomplish proximal retraction of deployment sheath 16. Numerous other actuation members are contemplated. A number of other structures and features of system 10 can be seen in FIG. 1 and are labeled with reference numbers. Additional discussion of these structures can be found below.



FIGS. 2-4 illustrate at least some of the structural components that may be included as a part of system 10. For example, system 10 may include an inner shaft or member 20 as illustrated in FIG. 2. In at least some embodiments, inner member 20 may be a tubular structure and, thus, may include a lumen (not shown). The lumen may be a guidewire lumen that extends along at least a portion of the length of inner member 20. Accordingly, system 10 may be advanced over a guidewire to the desired target location in the vasculature. In addition, or in alternative embodiments, the lumen may be a perfusion/aspiration lumen that allows portions, components, or all of system 10 to be flushed, perfused, aspirated, or the like.


Inner member 20 may include a stent receiving region 22 about which a stent (not shown, can be seen in FIGS. 3-4) may be disposed. The length and/or configuration of stent receiving region 22 may vary. For example, stent receiving region 22 may have a length sufficient for the stent to be disposed thereon. It can be appreciated that as the length of the stent utilized for system 10 increases, the length of stent receiving region 22 also increases.


Along or otherwise disposed adjacent stent receiving region 22 may be one or more perfusion ports 24. Ports 24 may extend through the wall of inner member 20 such that fluid may be infused through the lumen of inner member 20 and may be flushed through ports 24. This may be desirable for a number of reasons. For example, ports 24 may allow a clinician to evacuate air bubbles that may be trapped adjacent the stent by perfusing fluid through ports 24. In addition, ports 24 may be used to aspirate fluid that may be disposed along inner member 20. Ports 24 may also aid in sterilization and/or other preparatory processing steps that may be involved in preparing system 10 for use.


A tip 26 may be attached to or otherwise disposed at the distal end of inner member 20. Tip 26 may generally have a rounded or smooth shape that provides a generally atraumatic distal end to system 10. For example, tip 26 may have a smooth tapered distal portion 28 that gently tapers. Tip may also include a proximal ridge 30 that is configured so that sheath 16 can abut therewith. Tip 26 may also include a tapered proximal portion 33. Numerous other shapes and/or configurations are contemplated for tip 26.


Tip 26 may also include one or more cutouts or flats 32 formed therein. For the purposes of this disclosure, flats 32 are understood to be cutouts or flattened portions of tip 26 where the outer dimension or profile of tip 26 is reduced. The name “flats” comes from the fact that these regions may have a somewhat “flat” appearance when compared to the remainder of tip 26, which generally may have a rounded profile. The shape, however, of flats 32 is not meant to be limited to being flat or planar as numerous shapes are contemplated.


Flats 32 may allow for a gap or space to be defined between inner member 20 and deployment sheath 16 when sheath 16 abuts proximal ridge 30 of tip 26. This gap may allow for fluid, for example perfusion fluid passed through ports 24, to flow out from sheath 16. Thus, flats 32 may be used in conjunction with ports 24 to allow portions or all of system 10 to be flushed or otherwise evacuated of air bubbles.



FIG. 3 illustrates inner member 20 with some additional structure of system 10. In this figure, a stent 34 is disposed about inner member 20 (e.g., about stent receiving region 22 of inner member 20). In some embodiments, stent 34 is a self-expanding stent. Accordingly, stent 34 may be biased to outwardly expand. Because of this, stent 34 may not be “loaded onto” inner member 20 in a strict sense but rather may be thought of as being disposed about or surrounding inner member 20. Stent 34 may then be restrained within deployment sheath 16. In alternative embodiments, however, stent 34 may be directly loaded onto inner member 20 via crimping or any other suitable mechanical holding mechanism.


An intermediate tube 36 may also be disposed over inner member 20. In at least some embodiments, intermediate tube 36 may extend from a position adjacent to the proximal end of inner member 20 to a position proximal of the distal end of inner member 20. Intermediate tube 36 may include a bumper 38. In practice, bumper 38 may function by preventing any unwanted proximal movement of stent 38 during navigation and/or deployment of stent 38.


Bumper 38 may have any suitable form. In some embodiments, bumper 38 may be defined by a relatively short tube or sleeve that is disposed about intermediate tube 36. The material utilized for the sleeve may be the same or different from that of intermediate tube 36. Intermediate tube 36 may have a tapered or otherwise smooth transition in outer diameter adjacent bumper 38. For example, polymeric material may be disposed or reflowed adjacent bumper 38 (which may include disposing the polymeric material about a portion or all of bumper 38) so as to define a gentle transition in outer diameter at bumper 38. Other configurations are contemplated and may be utilized in alternative embodiments.



FIG. 4 illustrates additional structure of system 10. Here deployment sheath 16 can be seen disposed over inner member 20, intermediate tube 36, and stent 34. It can be appreciated that sheath 16 is configured to shift between a first position, for example as shown in FIG. 4, where sheath 16 overlies stent 34 and a second position where sheath 16 is proximally retracted to a position substantially proximal of stent 34. In general, the first position may be utilized during navigation of system 10 to the appropriate location within a body lumen and the second position may be used to deploy stent 34.


Sheath 16 may include a flared portion 40 where the outer diameter of sheath 16 is increased. In portion 40, the thickness of the tubular wall of sheath 16 may or may not be increased. Flared portion 40 may be desirable for a number of reasons. For example, flared portion 40 may allow sheath 16 to have an adequate inner dimension that is suitable so that sheath 16 may be disposed about stent 34 and bumper 38.



FIG. 4 also illustrates the distal end 46 of sheath 16 abutting proximal ridge 30. In this configuration, stent 34 can be flushed (e.g., to remove air bubbles) by infusing fluid through inner member 20 and through ports 24. Because of flats 32, fluid may be allowed to be flushed out of sheath 16 by passing through the gaps formed between inner member 20 and sheath 16 at flats 32.


Sheath 16 may also include a radiopaque marker or band 44. In general, marker band 44 may be disposed adjacent to the distal end 46 of sheath 16. One or more additional marker bands 44 may be disposed along other portions of sheath 16 or other portions of system 10. Marker band 44 may allow the distal end 46 of sheath 16 to be fluoroscopically visualized during advancement of system 10 and/or deployment of stent 34.


In at least some embodiments, sheath 16 may include a reinforcing member 42 embedded or otherwise included therewith. Reinforcing member 42 may have any number of a variety of different configurations. For example, reinforcing member 42 may include a braid, coil, mesh, combinations thereof, or the like, or any other suitable configuration. In some embodiments, reinforcing member 42 may extend along the entire length of sheath 16. In other embodiments, reinforcing member 42 may extend along one or more portions of the length of sheath 16. For example, reinforcing member 42 may extend along flared portion 40, along the distal portion of sheath, etc. In some instances, reinforcing member 42 may include a plurality of sections. For example, reinforcing member 42 may include a proximal section and a distal section. The proximal section and the distal section may be formed from the same materials or from different materials.


Sheath 16 is illustrated schematically in FIG. 6, with reinforcing member 42 shown in phantom line. Reinforcing member 42 may be formed from a suitable material such as those materials disclosed herein. In some instances, it may be desirable to visualize stent 34 through sheath 16 (and reinforcing member 42) prior to delivery and/or during delivery. Accordingly, reinforcing member 42 may be partially and/or substantially translucent, partially transparent, fully transparent, or otherwise sufficiently clear in order to allow a clinician to visualize stent 34 through reinforcing member 42. In some instances, reinforcing member 42 is formed from polyetheretherketone (PEEK). Other materials are contemplated including clear, translucent, or transparent materials. For example, reinforcing member 42 may include polyethylene terephthalate (PET), ultra-high molecular weight polyethylene (UHMWPE), or the like. In addition, sheath 16 may also be formed from material(s) that are partially and/or substantially translucent, partially transparent, fully transparent, or otherwise sufficiently clear in order to allow a clinician to visualize stent 34 therethrough.



FIG. 6 is a cross-sectional view of sheath 16 taken through line 6-6 in FIG. 5. Here it can be seen that sheath 16 may include multiple layers. For example, sheath 16 may include an inner layer or liner 50 and an outer layer 52. Reinforcing member 42 may be at least partially disposed between inner liner 50 and outer layer 52. Inner liner 50, outer layer 52, or both may be formed from a suitable material. In at least some instances, inner liner 50, outer layer 52, or both may be formed from material(s) that are partially and/or substantially translucent, partially transparent, fully transparent, or otherwise sufficiently clear in order to allow a clinician to visualize stent 34 therethrough.


In addition to permitting visualization, sheath 16 may also provide other desirable features. For example, in some instances stent 34 may be a self-expanding stent. Self-expanding stents may have a tendency to exert an outward radial force when restrained, for example onto sheath 16. In some instances, the outward radial forces exerted on sheath could lead to the stent 34 deforming or otherwise “digging into” the inner surface of sheath 16. This may increase the amount of force required to pull back sheath 16 and deploy stent 34. Reinforcing member 42 may help to reduce deformation along the inner surface of sheath 16, thereby reducing the deployment forces. For example, FIG. 7 schematically illustrates a force F (e.g., a radially outward force being exerted by stent 34) being applied to sheath 16. Reinforcing member 42 may reduce the amount of deformation along sheath 16. For example, the force F may cause little or no deformation of sheath 16 and, in FIG. 7, is schematically shown as a deformation/deflection of a distance D1. For example, when an axial stress of about 5-10 lbs or about 8 lbs of force is applied, strain may be kept at about 0.1 to 0.2 inches or less, or about 0.1 inches or less. In contrast, a sheath 116 including inner liner 150 and outer layer 152 (e.g., as shown in FIG. 8) but lacking reinforcing member 42, may be subjected to addition deformation/deflection of a distance D2, where D2 would be larger than D1, increasing the “digging in” of the stent 34 to the inner surface of the sheath 116, thereby increasing the force required to pull back the sheath 116 to deploy stent 34.


Without wishing to be bound by theory, when stent 34 applies outward pressure onto a structure constraining it (e.g., sheath 16 or sheath 116), assuming similar dimensions, the structure that includes materials with a larger elastic modulus or hardness (e.g., sheath 16 including reinforcing member 42) may be more resistance to stent movement or “creep” over time. In addition, stent 34 should also “dig in” less. Collectively, these features may reduce deployment forces. In addition, reinforcing member 42 may also reduce or otherwise limit axial strain, which may also reduce transverse strain (e.g., based on the material's property for Poisson's Ratio), thereby reducing the pressure/force between stent 34 and sheath 16. Axial strain could result in the inner diameter of sheath 16 reducing. Therefore, reducing axial strain also helps to reduce deployment force by reducing axial strain-related decreases in inner diameter.


In some instances, reinforcing member 42 may include other structural variations. For example, in embodiments where reinforcing member 42 includes a braid, the pic count may vary. In some instances, reinforcing member 42 may have a “relatively high” pic count (e.g., about 90-150 pics per inch) to add flexibility and reduce kinks around a tight radius. In some instances, reinforcing member 42 may have a lower pic count (e.g., about 40-72 pics per inch) to increase pushability/torqueability to outer sheath 16. Other variations are contemplated.



FIG. 9 illustrates sheath 16 positioned over stent 34 and inner member 20. Again, reinforcing member 42 is shown in phantom line to schematically illustrate that stent 34 can be visualized through reinforcing member 42 (and/or sheath 16). In some instances, system 10 may be used along the biliary tract, enteral tract, an airway, or the like. Such interventions may include the use of a visualization device such as an endoscopic visualization device. The use of translucent reinforcing member 42 may allow for the endoscopic visualization device to directly visualize stent 34 within sheath 16, for example, before and/or during deployment.


Manufacturing sheath 16 may include a number of steps. For example, manufacturing sheath 16 may include disposing inner liner 50 along a mandrel. In some instances, liner 50 may be stretched and secured at its ends to the mandrel. Reinforcing member 42 may be disposed over liner 50. This may include disposing reinforcing member 42 over one or more discrete portions of liner 50 (e.g., a distal portion) or along the full length of liner 50. When reinforcing member 42 takes the form of a braid, reinforcement may be braided in a braid pattern that has about 52-90 pic/inch. In some instances, an additional reinforcement (not shown) may be disposed over the proximal section of liner 50 (e.g., which may include disposing the additional reinforcement over the proximal portion of reinforcing member 42). The additional reinforcement may take the form of a metallic braid (e.g., stainless steel or other suitable materials). Outer layer 52 may be disposed over liner 50 and reinforcing member 42 (and the additional reinforcement, if present). In some instances, a radiopaque marker band may be disposed over a portion of liner 50 prior to the addition of outer layer 52. A heat shrink material (e.g., fluorinated ethylene propylene) may be disposed over the entire assembly and heat may be added to reflow/laminate adjacent tubes/layers together. When doing so, reinforcing member 42 may be encapsulated and outer layer 52 may be mechanically bonded to liner 50. Any excess portion of liner 50 may be skived off and the resultant structure may be trimmed to the desired length and removed from the mandrel. The manufacturing of system may include manufacturing sheath 16, disposing inner member 20 within sheath 16, and disposing stent 34 between sheath 16 and inner member 20.


The materials that can be used for the various components of system 10 (and/or other systems disclosed herein) may include those commonly associated with medical devices. For simplicity purposes, the following discussion makes reference to shaft 12, deployment sheath 16, and inner member 20. However, this is not intended to limit the invention as the discussion may be applied to other similar members and/or components of members or systems disclosed herein.


Shaft 12, deployment sheath 16, and inner member 20, and/or other components of system 10 may be made from a metal, metal alloy, polymer (some examples of which are disclosed below), a metal-polymer composite, combinations thereof, and the like, or any other suitable material. Some examples of suitable metals and metal alloys include stainless steel, such as 304V, 304L, and 316LV stainless steel; mild steel; nickel-titanium alloy such as linear-elastic and/or super-elastic nitinol; other nickel alloys such as nickel-chromium-molybdenum alloys (e.g., UNS: N06625 such as INCONEL® 625, UNS: N06022 such as HASTELLOY® C-22®, UNS: N10276 such as HASTELLOY® C276®, other HASTELLOY® alloys, and the like), nickel-copper alloys (e.g., UNS: N04400 such as MONEL® 400, NICKELVAC® 400, NICORROS® 400, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nickel-molybdenum alloys (e.g., UNS: N10665 such as HASTELLOY® ALLOY B2®), other nickel-chromium alloys, other nickel-molybdenum alloys, other nickel-cobalt alloys, other nickel-iron alloys, other nickel-copper alloys, other nickel-tungsten or tungsten alloys, and the like; cobalt-chromium alloys; cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like); platinum enriched stainless steel; titanium; combinations thereof; and the like; or any other suitable material.


As alluded to above, within the family of commercially available nickel-titanium or nitinol alloys, is a category designated “linear elastic” or “non-super-elastic” which, although may be similar in chemistry to conventional shape memory and super elastic varieties, may exhibit distinct and useful mechanical properties. Linear elastic and/or non-super-elastic nitinol may be distinguished from super elastic nitinol in that the linear elastic and/or non-super-elastic nitinol does not display a substantial “superelastic plateau” or “flag region” in its stress/strain curve like super elastic nitinol does. Instead, in the linear elastic and/or non-super-elastic nitinol, as recoverable strain increases, the stress continues to increase in a substantially linear, or a somewhat, but not necessarily entirely linear relationship until plastic deformation begins or at least in a relationship that is more linear that the super elastic plateau and/or flag region that may be seen with super elastic nitinol. Thus, for the purposes of this disclosure linear elastic and/or non-super-elastic nitinol may also be termed “substantially” linear elastic and/or non-super-elastic nitinol.


In some cases, linear elastic and/or non-super-elastic nitinol may also be distinguishable from super elastic nitinol in that linear elastic and/or non-super-elastic nitinol may accept up to about 2-5% strain while remaining substantially elastic (e.g., before plastically deforming) whereas super elastic nitinol may accept up to about 8% strain before plastically deforming. Both of these materials can be distinguished from other linear elastic materials such as stainless steel (that can also can be distinguished based on its composition), which may accept only about 0.2-0.44% strain before plastically deforming.


In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy is an alloy that does not show any martensite/austenite phase changes that are detectable by DSC and DMTA analysis over a large temperature range. For example, in some embodiments, there may be no martensite/austenite phase changes detectable by DSC and DMTA analysis in the range of about −60° C. to about 120° C. in the linear elastic and/or non-super-elastic nickel-titanium alloy. The mechanical bending properties of such material may therefore be generally inert to the effect of temperature over this very broad range of temperature. In some embodiments, the mechanical bending properties of the linear elastic and/or non-super-elastic nickel-titanium alloy at ambient or room temperature are substantially the same as the mechanical properties at body temperature, for example, in that they do not display a super-elastic plateau and/or flag region. In other words, across a broad temperature range, the linear elastic and/or non-super-elastic nickel-titanium alloy maintains its linear elastic and/or non-super-elastic characteristics and/or properties and has essentially no yield point.


In some embodiments, the linear elastic and/or non-super-elastic nickel-titanium alloy may be in the range of about 50 to about 60 weight percent nickel, with the remainder being essentially titanium. In some embodiments, the composition is in the range of about 54 to about 57 weight percent nickel. One example of a suitable nickel-titanium alloy is FHP-NT alloy commercially available from Furukawa Techno Material Co. of Kanagawa, Japan. Some examples of nickel titanium alloys are disclosed in U.S. Pat. Nos. 5,238,004 and 6,508,803, which are incorporated herein by reference. Other suitable materials may include ULTANIUM™ (available from Neo-Metrics) and GUM METAL™ (available from Toyota). In some other embodiments, a superelastic alloy, for example a superelastic nitinol can be used to achieve desired properties.


In at least some embodiments, portions or all of shaft 12, deployment sheath 16, and inner member 20 may also be doped with, made of, or otherwise include a radiopaque material including those listed herein or other suitable radiopaque materials.


In some embodiments, a degree of Mill compatibility is imparted into system 10. For example, to enhance compatibility with Magnetic Resonance Imaging (Mill) machines, it may be desirable to make shaft 12, deployment sheath 16, and inner member 20, in a manner that would impart a degree of MRI compatibility. For example, shaft 12, deployment sheath 16, and inner member 20, or portions thereof, may be made of a material that does not substantially distort the image and create substantial artifacts (artifacts are gaps in the image). Certain ferromagnetic materials, for example, may not be suitable because they may create artifacts in an Mill image. Shaft 12, deployment sheath 16, and inner member 20, or portions thereof, may also be made from a material that the Mill machine can image. Some materials that exhibit these characteristics include, for example, tungsten, cobalt-chromium-molybdenum alloys (e.g., UNS: R30003 such as ELGILOY®, PHYNOX®, and the like), nickel-cobalt-chromium-molybdenum alloys (e.g., UNS: R30035 such as MP35-N® and the like), nitinol, and the like, and others.


Some examples of suitable polymers that may be used to form shaft 12, deployment sheath 16, and inner member 20, and/or other components of system 10 may include polytetrafluoroethylene (PTFE), ethylene tetrafluoroethylene (ETFE), fluorinated ethylene propylene (FEP), polyoxymethylene (POM, for example, DELRIN® available from DuPont), polyether block ester, polyurethane (for example, Polyurethane 85A), polypropylene (PP), polyvinylchloride (PVC), polyether-ester (for example, ARNITEL® available from DSM Engineering Plastics), ether or ester based copolymers (for example, butylene/poly(alkylene ether) phthalate and/or other polyester elastomers such as HYTREL® available from DuPont), polyamide (for example, DURETHAN® available from Bayer or CRISTAMID® available from Elf Atochem), elastomeric polyamides, block polyamide/ethers, polyether block amide (PEBA, for example available under the trade name PEBAX®), ethylene vinyl acetate copolymers (EVA), silicones, polyethylene (PE), Marlex high-density polyethylene, Marlex low-density polyethylene, linear low density polyethylene (for example REXELL®), polyester, polybutylene terephthalate (PBT), polyethylene terephthalate (PET), polytrimethylene terephthalate, polyethylene naphthalate (PEN), polyetheretherketone (PEEK), polyimide (PI), polyetherimide (PEI), polyphenylene sulfide (PPS), polyphenylene oxide (PPO), poly paraphenylene terephthalamide (for example, KEVLAR®), polysulfone, nylon, nylon-12 (such as GRILAMID® and/or GRILAMID® TR55-LX available from EMS American Grilon), perfluoro(propyl vinyl ether) (PFA), ethylene vinyl alcohol, polyolefin, polystyrene, epoxy, polyvinylidene chloride (PVdC), poly(styrene-b-isobutylene-b-styrene) (for example, SIBS and/or SIBS 50A), polycarbonates, ionomers, biocompatible polymers, other suitable materials, or mixtures, combinations, copolymers thereof, polymer/metal composites, and the like. In some embodiments the sheath can be blended with a liquid crystal polymer (LCP). For example, the mixture can contain up to about 6% LCP.


In some embodiments, the exterior surface of the system 10 may include a coating, for example a lubricious, a hydrophilic, a protective, or other type of coating. Hydrophobic coatings such as fluoropolymers provide a dry lubricity which improves device handling and exchanges. Lubricious coatings improve steerability and improve lesion crossing capability. Suitable lubricious polymers may include silicone and the like, polymers such as high-density polyethylene (HDPE), polytetrafluoroethylene (PTFE), polyarylene oxides, polyvinylpyrolidones, polyvinylalcohols, hydroxy alkyl cellulosics, algins, saccharides, caprolactones, and the like, and mixtures and combinations thereof. Hydrophilic polymers may be blended among themselves or with formulated amounts of water insoluble compounds (including some polymers) to yield coatings with suitable lubricity, bonding, and solubility. Some other examples of such coatings and materials and methods used to create such coatings can be found in U.S. Pat. Nos. 6,139,510 and 5,772,609, the entire disclosures of which are incorporated herein by reference.


U.S. Pat. Nos. 9,084,692 and 8,784,468 as well as U.S. Patent Application Pub. No. US 2013/0013047 are incorporated herein.


It should be understood that this disclosure is, in many respects, only illustrative. Changes may be made in details, particularly in matters of shape, size, and arrangement of steps without exceeding the scope of the invention. The invention's scope is, of course, defined in the language in which the appended claims are expressed.

Claims
  • 1. A stent delivery system, comprising: an inner member;a deployment sheath disposed about the inner member, wherein at least a distal region of the deployment sheath is translucent;a stent disposed between the inner member and the deployment sheath; anda translucent reinforcing member disposed within the translucent distal region of the deployment sheath, wherein the translucent reinforcing member and the translucent distal region of the deployment sheath allow for visualization of the stent during stent deployment.
  • 2. The stent delivery system of claim 1, wherein the stent includes a self-expanding stent.
  • 3. The stent delivery system of claim 1, wherein the translucent reinforcing member includes a braid.
  • 4. The stent delivery system of claim 1, wherein the translucent reinforcing member includes a coil.
  • 5. The stent delivery system of claim 1, wherein the translucent reinforcing member includes a polymer.
  • 6. The stent delivery system of claim 1, wherein the translucent reinforcing member includes polyetheretherketone.
  • 7. The stent delivery system of claim 1, wherein the deployment sheath extends from a proximal end of the deployment sheath to a distal end of the deployment sheath.
  • 8. The stent delivery system of claim 1, wherein the deployment sheath has a proximal region, and wherein the translucent reinforcing member extends along the translucent distal region.
  • 9. The stent delivery system of claim 8, wherein the translucent distal region has an enlarged outer diameter relative to the proximal region, an enlarged inner diameter relative to the proximal region, or both.
  • 10. The stent delivery system of claim 1, wherein the deployment sheath includes an inner liner and an outer layer, and wherein at least a portion of the translucent reinforcing member is disposed between the inner liner and the outer layer.
  • 11. The stent delivery system of claim 10, wherein the inner liner, the outer layer, or both are at least partially translucent.
  • 12. The stent delivery system of claim 1, further comprising a handle coupled to the inner member and to the deployment sheath, the handle including an actuation member capable of translating the deployment sheath relative to the inner member.
  • 13. A stent delivery system for use along a biliary tract, an enteral tract, or an airway, the stent delivery system comprising: an inner member;a deployment sheath disposed about the inner member;a self-expanding stent disposed between the inner member and the deployment sheath; andwherein the deployment sheath includes an inner liner, an outer layer, and a translucent braided reinforcing member disposed at least partially between the inner liner and the outer layer;wherein the inner liner and the outer layer are translucent; andwherein the inner liner, the outer layer, and the translucent braided reinforcing member allow for visualization of the self-expanding stent during stent deployment.
  • 14. The stent delivery system of claim 13, wherein the translucent braided reinforcing member includes a polymer.
  • 15. The stent delivery system of claim 13, wherein the translucent braided reinforcing member includes polyetheretherketone.
  • 16. The stent delivery system of claim 13, wherein the deployment sheath has a proximal region and a distal region, and wherein the translucent braided reinforcing member extends along at least the distal region.
  • 17. The stent delivery system of claim 16, wherein the distal region has an enlarged outer diameter relative to the proximal region, an enlarged inner diameter relative to the proximal region, or both.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority under 35 U.S.C. § 119 to U.S. Provisional Application Ser. No. 62/255,837, filed Nov. 16, 2015, the entirety of which is incorporated herein by reference.

US Referenced Citations (478)
Number Name Date Kind
1553227 Feyk et al. Sep 1925 A
1866888 Hawley Jul 1932 A
2275827 Plensler Mar 1942 A
2413805 Vickers Jan 1947 A
2441166 Raspet May 1948 A
2561890 Stoddard Jul 1951 A
2722614 Fryklund Nov 1955 A
2857536 Light Oct 1958 A
2864017 Waltscheff Dec 1958 A
2871793 Michie et al. Feb 1959 A
3249776 Anderson et al. May 1966 A
3322984 Anderson May 1967 A
3334523 Rieser Aug 1967 A
3363470 Yavne Jan 1968 A
3452227 Welch Jun 1969 A
3452742 Muller Jul 1969 A
3463953 Maxwell Aug 1969 A
3512019 Durand May 1970 A
3544868 Bates Dec 1970 A
3613684 Sheridan Oct 1971 A
3625200 Muller Dec 1971 A
3686990 Margolien Aug 1972 A
3841308 Tate Oct 1974 A
3890977 Wilson Jun 1975 A
3906938 Fleischhacker Sep 1975 A
4000672 Sitterer et al. Jan 1977 A
4003369 Heilman et al. Jan 1977 A
4020829 Willson et al. May 1977 A
4142119 Madey Feb 1979 A
4215703 Willson Aug 1980 A
4318402 Vaillancourt Mar 1982 A
4330725 Hintz May 1982 A
4425919 Alston, Jr. et al. Jan 1984 A
4476754 Ducret Oct 1984 A
4482828 Vergues et al. Nov 1984 A
4545390 Leary Oct 1985 A
4547192 Brodsky et al. Oct 1985 A
4563181 Wijayarathna et al. Jan 1986 A
4574670 Johnson Mar 1986 A
4580551 Siegmund et al. Apr 1986 A
4583404 Bernard et al. Apr 1986 A
4635270 Gurs Jan 1987 A
4665906 Jervis May 1987 A
4665918 Garza et al. May 1987 A
4721117 Mar et al. Jan 1988 A
4732152 Wallsten et al. Mar 1988 A
4737153 Shimamura et al. Apr 1988 A
4763647 Gambale Aug 1988 A
4774949 Fogarty Oct 1988 A
4781092 Gaiser Nov 1988 A
4781186 Simpson et al. Nov 1988 A
4786220 Fildes et al. Nov 1988 A
4790331 Okada et al. Dec 1988 A
4800890 Cramer Jan 1989 A
4811743 Stevens Mar 1989 A
4827941 Taylor et al. May 1989 A
4831858 Yoshizawa et al. May 1989 A
4832047 Sepetka et al. May 1989 A
4846186 Box et al. Jul 1989 A
4846193 Tremulis et al. Jul 1989 A
4867173 Leoni Sep 1989 A
4875489 Messner et al. Oct 1989 A
4884579 Engelson Dec 1989 A
4906232 Reynolds Mar 1990 A
4911148 Sosnowski et al. Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922164 Jacobsen et al. May 1990 A
4922777 Kawabata May 1990 A
4932959 Horzewski et al. Jun 1990 A
4934380 De Toledo Jun 1990 A
4953553 Tremulis Sep 1990 A
4954022 Underwood et al. Sep 1990 A
4955384 Taylor et al. Sep 1990 A
4955862 Sepetka Sep 1990 A
4960410 Pinchuk Oct 1990 A
4964409 Tremulis Oct 1990 A
4966163 Kraus et al. Oct 1990 A
4968306 Huss et al. Nov 1990 A
4985022 Fearnot et al. Jan 1991 A
4989608 Ratner Feb 1991 A
4990143 Sheridan Feb 1991 A
4994069 Ritchart et al. Feb 1991 A
4998923 Samson et al. Mar 1991 A
5007434 Doyle et al. Apr 1991 A
5009137 Dannatt Apr 1991 A
5026377 Burton et al. Jun 1991 A
5040543 Badera et al. Aug 1991 A
5050606 Tremulis Sep 1991 A
5052404 Hodgson Oct 1991 A
5059177 Towne et al. Oct 1991 A
5063935 Gambale Nov 1991 A
5071407 Termin et al. Dec 1991 A
5095915 Engelson Mar 1992 A
5106455 Jacobsen et al. Apr 1992 A
5109830 Cho May 1992 A
5125395 Adair Jun 1992 A
5135531 Shiber Aug 1992 A
5144959 Gambale et al. Sep 1992 A
5147317 Shank et al. Sep 1992 A
5158548 Lau et al. Oct 1992 A
5163905 Don Michael Nov 1992 A
5181668 Tsuji et al. Jan 1993 A
5195984 Schatz Mar 1993 A
5201757 Heyn et al. Apr 1993 A
5205830 Dassa et al. Apr 1993 A
5211183 Wilson May 1993 A
5221261 Termin et al. Jun 1993 A
5228441 Lundquist Jul 1993 A
5234416 Macaulay et al. Aug 1993 A
5238004 Sahatjian et al. Aug 1993 A
5242759 Hall Sep 1993 A
5243996 Hall Sep 1993 A
5250069 Nobuyoshi et al. Oct 1993 A
5254106 Feaster Oct 1993 A
5254107 Soltesz Oct 1993 A
5256144 Kraus et al. Oct 1993 A
5257974 Cox Nov 1993 A
5259393 Corso, Jr. et al. Nov 1993 A
5267979 Appling et al. Dec 1993 A
5267982 Sylvanowicz Dec 1993 A
5279562 Sirhan et al. Jan 1994 A
5284128 Hart Feb 1994 A
5300032 Hibbs et al. Apr 1994 A
5304131 Paskar Apr 1994 A
5306252 Yutori et al. Apr 1994 A
5308435 Ruggles et al. May 1994 A
5315906 Ferenczi et al. May 1994 A
5315996 Lundquist May 1994 A
5322064 Lundquist Jun 1994 A
5329923 Lundquist Jul 1994 A
5333620 Moutafis et al. Aug 1994 A
5334145 Lundquist et al. Aug 1994 A
5336205 Zenzen et al. Aug 1994 A
5341818 Abrams et al. Aug 1994 A
5345937 Middleman et al. Sep 1994 A
5345945 Hodgson et al. Sep 1994 A
5346471 Raulerson Sep 1994 A
5358493 Schweich, Jr. et al. Oct 1994 A
5365942 Shank Nov 1994 A
5365943 Jansen Nov 1994 A
5368564 Savage Nov 1994 A
5376084 Bacich et al. Dec 1994 A
5378239 Termin et al. Jan 1995 A
5381782 DeLaRama et al. Jan 1995 A
5406960 Corso, Jr. Apr 1995 A
5411476 Abrams et al. May 1995 A
5433723 Lindenberg et al. Jul 1995 A
5437288 Schwartz et al. Aug 1995 A
5438993 Lynch et al. Aug 1995 A
5439000 Gunderson et al. Aug 1995 A
5441483 Avitall Aug 1995 A
5441489 Utsumi et al. Aug 1995 A
5443907 Slaikeu et al. Aug 1995 A
5445646 Euteneuer et al. Aug 1995 A
5447812 Fukuda et al. Sep 1995 A
5454787 Lundquist Oct 1995 A
5460187 Daigle et al. Oct 1995 A
5470330 Goldenberg et al. Nov 1995 A
5476701 Berger Dec 1995 A
5477856 Lundquist Dec 1995 A
5480382 Hammerslag et al. Jan 1996 A
5496277 Termin et al. Mar 1996 A
5496294 Hergenrother et al. Mar 1996 A
5497785 Viera Mar 1996 A
5507301 Wasicek et al. Apr 1996 A
5507729 Lindenberg et al. Apr 1996 A
5507751 Goode et al. Apr 1996 A
5507766 Kugo et al. Apr 1996 A
5514128 Hillsman et al. May 1996 A
5520194 Miyata et al. May 1996 A
5520645 Imran et al. May 1996 A
5531719 Takahashi Jul 1996 A
5533985 Wang Jul 1996 A
5534007 St. Germain et al. Jul 1996 A
5546958 Thorud et al. Aug 1996 A
5551444 Finlayson Sep 1996 A
5554139 Okajima Sep 1996 A
5562619 Mirarchi et al. Oct 1996 A
5569197 Helmus et al. Oct 1996 A
5569200 Umeno et al. Oct 1996 A
5569218 Berg Oct 1996 A
5571073 Castillo Nov 1996 A
5571135 Fraser et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5584821 Hobbs et al. Dec 1996 A
5599326 Carter Feb 1997 A
5599492 Engelson Feb 1997 A
5601539 Corso, Jr. Feb 1997 A
5605162 Mirazee et al. Feb 1997 A
5622184 Ashby et al. Apr 1997 A
5630806 Inagaki et al. May 1997 A
5637089 Abrams et al. Jun 1997 A
5656011 Uihlein et al. Aug 1997 A
5658264 Samson Aug 1997 A
5662703 Yurek et al. Sep 1997 A
5666968 Imran et al. Sep 1997 A
5666969 Urick et al. Sep 1997 A
5669926 Aust et al. Sep 1997 A
5674242 Phan et al. Oct 1997 A
5676659 McGurk Oct 1997 A
5676697 McDonald Oct 1997 A
5682894 Orr et al. Nov 1997 A
5690120 Jacobsen et al. Nov 1997 A
5690644 Yurek et al. Nov 1997 A
5695499 Helgerson et al. Dec 1997 A
5702364 Euteneuer et al. Dec 1997 A
5702373 Samson Dec 1997 A
5713860 Kaplan et al. Feb 1998 A
5720300 Fagan et al. Feb 1998 A
5722609 Murakami Mar 1998 A
5728063 Preissman et al. Mar 1998 A
5733267 Del Toro Mar 1998 A
5741429 Donadio, III et al. Apr 1998 A
5746701 Noone May 1998 A
5755777 Chuter May 1998 A
5769830 Parker Jun 1998 A
5772609 Nguyen et al. Jun 1998 A
5772669 Vrba Jun 1998 A
5782809 Umeno et al. Jul 1998 A
5788653 Lorenzo Aug 1998 A
5788654 Schwager Aug 1998 A
5788707 Del Toro et al. Aug 1998 A
5792124 Horrigan et al. Aug 1998 A
5797856 Frisbie et al. Aug 1998 A
5800454 Jacobsen et al. Sep 1998 A
5807075 Jacobsen et al. Sep 1998 A
5807249 Qin et al. Sep 1998 A
5810885 Zinger Sep 1998 A
5813996 St. Germain et al. Sep 1998 A
5827225 Schwab Oct 1998 A
5827242 Follmer et al. Oct 1998 A
5830181 Thornton Nov 1998 A
5833632 Jacobsen et al. Nov 1998 A
5833694 Poncet Nov 1998 A
5833706 St. Germain et al. Nov 1998 A
5836923 Mayer Nov 1998 A
5836926 Peterson et al. Nov 1998 A
5843050 Jones et al. Dec 1998 A
5843090 Schuetz Dec 1998 A
5843091 Holsinger et al. Dec 1998 A
5843244 Pelton et al. Dec 1998 A
5851203 van Muiden Dec 1998 A
5882347 Mouris-Laan et al. Mar 1999 A
5891154 Loeffler Apr 1999 A
5895378 Nita Apr 1999 A
5897537 Berg et al. Apr 1999 A
5902254 Magram May 1999 A
5902290 Peacock, III et al. May 1999 A
5904657 Unsworth et al. May 1999 A
5906618 Larson, III May 1999 A
5906619 Olson et al. May 1999 A
5911715 Berg et al. Jun 1999 A
5911717 Jacobsen et al. Jun 1999 A
5916177 Schwager Jun 1999 A
5916178 Noon et al. Jun 1999 A
5916194 Jacobsen et al. Jun 1999 A
5931830 Jacobsen et al. Aug 1999 A
5935108 Katoh et al. Aug 1999 A
5947940 Beisel Sep 1999 A
5951539 Nita et al. Sep 1999 A
5954764 Parodi Sep 1999 A
5957930 Vrba Sep 1999 A
5971975 Mills et al. Oct 1999 A
5980483 Dimitri Nov 1999 A
6001068 Uchino et al. Dec 1999 A
6004279 Crowley et al. Dec 1999 A
6014919 Jacobsen et al. Jan 2000 A
6017319 Jacobsen et al. Jan 2000 A
6017577 Hostettler et al. Jan 2000 A
6019778 Wilson et al. Feb 2000 A
6022343 Johnson et al. Feb 2000 A
6022369 Jacobsen et al. Feb 2000 A
6024730 Pagan Feb 2000 A
6027461 Walker et al. Feb 2000 A
6033413 Mikus et al. Mar 2000 A
6042553 Solar et al. Mar 2000 A
6045547 Ren et al. Apr 2000 A
6048339 Zirps et al. Apr 2000 A
6056702 Lorenzo May 2000 A
6059813 Vrba et al. May 2000 A
6063101 Jacobsen et al. May 2000 A
6063200 Jacobsen et al. May 2000 A
6066361 Jacobsen et al. May 2000 A
6106485 McMahon Aug 2000 A
6106488 Fleming et al. Aug 2000 A
6117140 Munsinger Sep 2000 A
6120522 Vrba et al. Sep 2000 A
6123723 Konya et al. Sep 2000 A
6139510 Palermo Oct 2000 A
6139524 Killion Oct 2000 A
6165292 Abrams et al. Dec 2000 A
6171296 Chow Jan 2001 B1
6176849 Yang et al. Jan 2001 B1
6183410 Jacobsen et al. Feb 2001 B1
6193686 Estrada et al. Feb 2001 B1
6197014 Samson et al. Mar 2001 B1
6203485 Urick Mar 2001 B1
6206888 Bicek et al. Mar 2001 B1
6214042 Jacobsen et al. Apr 2001 B1
6221467 Nazarova et al. Apr 2001 B1
6228073 Noone et al. May 2001 B1
6238410 Vrba et al. May 2001 B1
6248082 Jafari Jun 2001 B1
6251092 Qin et al. Jun 2001 B1
6254549 Ramzipoor Jul 2001 B1
6254609 Vrba et al. Jul 2001 B1
6260458 Jacobsen et al. Jul 2001 B1
6273404 Holman et al. Aug 2001 B1
6273876 Klima et al. Aug 2001 B1
6287329 Duerig et al. Sep 2001 B1
6290656 Boyle et al. Sep 2001 B1
6296616 McMahon Oct 2001 B1
6296631 Chow Oct 2001 B2
6302870 Jacobsen et al. Oct 2001 B1
6322586 Monroe et al. Nov 2001 B1
6325790 Trotta et al. Dec 2001 B1
6330884 Kim Dec 2001 B1
6331184 Abrams Dec 2001 B1
6338725 Hermann et al. Jan 2002 B1
6342066 Toro et al. Jan 2002 B1
6346091 Jacobsen et al. Feb 2002 B1
6352515 Anderson et al. Mar 2002 B1
6355005 Powell et al. Mar 2002 B1
6355027 Le et al. Mar 2002 B1
6355060 Lenker et al. Mar 2002 B1
6368315 Gillis et al. Apr 2002 B1
6368316 Jansen et al. Apr 2002 B1
6375628 Zadno-Azizi et al. Apr 2002 B1
6375676 Cox Apr 2002 B1
6375774 Lunn et al. Apr 2002 B1
6379365 Diaz Apr 2002 B1
6379369 Abrams et al. Apr 2002 B1
6380457 Yurek et al. Apr 2002 B1
6390993 Cornish et al. May 2002 B1
6391050 Broome May 2002 B1
6398758 Jacobsen et al. Jun 2002 B1
6398802 Yee Jun 2002 B1
6425898 Wilson et al. Jul 2002 B1
6428489 Jacobsen et al. Aug 2002 B1
6428512 Anderson et al. Aug 2002 B1
6431039 Jacobsen et al. Aug 2002 B1
6440088 Jacobsen et al. Aug 2002 B1
6478778 Jacobsen et al. Nov 2002 B1
6488637 Eder et al. Dec 2002 B1
6491648 Cornish et al. Dec 2002 B1
6491671 Larson, III et al. Dec 2002 B1
6503244 Hayman Jan 2003 B2
6508803 Horikawa et al. Jan 2003 B1
6514228 Hamilton et al. Feb 2003 B1
6514261 Randall et al. Feb 2003 B1
6524301 Wilson et al. Feb 2003 B1
6530934 Jacobsen et al. Mar 2003 B1
6544278 Vrba et al. Apr 2003 B1
6547779 Levine et al. Apr 2003 B2
6553880 Jacobsen et al. Apr 2003 B2
6556873 Smits Apr 2003 B1
6576006 Limon et al. Jun 2003 B2
6579246 Jacobsen et al. Jun 2003 B2
6589251 Yee et al. Jul 2003 B2
6602226 Smith et al. Aug 2003 B1
6602280 Chobotov Aug 2003 B2
6610046 Usami et al. Aug 2003 B1
6613014 Chi Sep 2003 B1
6623448 Slater Sep 2003 B2
6626934 Blaeser et al. Sep 2003 B2
6636758 Sanchez et al. Oct 2003 B2
6638266 Wilson et al. Oct 2003 B2
6652508 Griffin et al. Nov 2003 B2
6669716 Gilson et al. Dec 2003 B1
6682493 Mirigian Jan 2004 B2
6712826 Lui Mar 2004 B2
6726712 Raeder-Devens et al. Apr 2004 B1
6726714 DiCaprio et al. Apr 2004 B2
6730095 Olson, Jr. et al. May 2004 B2
6736839 Cummings May 2004 B2
6749560 Konstorum et al. Jun 2004 B1
6749627 Thompson et al. Jun 2004 B2
6755855 Yurek et al. Jun 2004 B2
6766720 Jacobsen et al. Jul 2004 B1
6773446 Dwyer et al. Aug 2004 B1
6776791 Stallings et al. Aug 2004 B1
6777644 Peacock, III et al. Aug 2004 B2
6802849 Blaeser et al. Oct 2004 B2
6811544 Schaer Nov 2004 B2
6837898 Boyle et al. Jan 2005 B2
6860898 Stack et al. Mar 2005 B2
6866642 Kellerman et al. Mar 2005 B2
6887235 O'Connor et al. May 2005 B2
6918882 Skujins et al. Jul 2005 B2
6939352 Buzzard et al. Sep 2005 B2
6942682 Vrba et al. Sep 2005 B2
6951675 Chin et al. Oct 2005 B2
6997937 Jacobsen et al. Feb 2006 B2
7001369 Griffin et al. Feb 2006 B2
7001423 Euteneuer et al. Feb 2006 B2
7074197 Reynolds et al. Jul 2006 B2
7278998 Gaschino et al. Oct 2007 B2
7387640 Cummings Jun 2008 B2
7540865 Griffin et al. Jun 2009 B2
7632296 Malewicz Dec 2009 B2
7740652 Gerdts et al. Jun 2010 B2
7914466 Davis et al. Mar 2011 B2
7955272 Rooney et al. Jun 2011 B2
8048004 Davis et al. Nov 2011 B2
8048060 Griffin et al. Nov 2011 B2
8128676 Cummings Mar 2012 B2
8152818 Gunderson Apr 2012 B2
8182465 Griffin et al. May 2012 B2
8753328 Aherne Jun 2014 B2
8784468 Gerdts et al. Jul 2014 B2
8858530 Nishigishi Oct 2014 B2
9084692 Hacker et al. Jul 2015 B2
20010034548 Vrba et al. Oct 2001 A1
20010034549 Bartholf et al. Oct 2001 A1
20010037141 Yee et al. Nov 2001 A1
20020013540 Jacobsen et al. Jan 2002 A1
20020019599 Rooney et al. Feb 2002 A1
20020052641 Monroe et al. May 2002 A1
20020058951 Fiedler May 2002 A1
20020082550 Hamilton et al. Jun 2002 A1
20020095203 Thompson et al. Jul 2002 A1
20020103525 Cummings Aug 2002 A1
20020165523 Chin et al. Nov 2002 A1
20030009208 Snyder et al. Jan 2003 A1
20030060732 Jacobsen et al. Mar 2003 A1
20030069520 Skujins et al. Apr 2003 A1
20030069521 Reynolds et al. Apr 2003 A1
20030069522 Jacobsen et al. Apr 2003 A1
20030139759 Schaible Jul 2003 A1
20030163156 Hebert et al. Aug 2003 A1
20040098083 Tran et al. May 2004 A1
20040148009 Buzzard et al. Jul 2004 A1
20040167437 Sharrow et al. Aug 2004 A1
20040181174 Davis et al. Sep 2004 A2
20040181176 Jafar et al. Sep 2004 A1
20040215317 Cummings Oct 2004 A1
20040267348 Gunderson et al. Dec 2004 A1
20050027345 Horan et al. Feb 2005 A1
20050080476 Gunderson et al. Apr 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050154439 Gunderson Jul 2005 A1
20050182475 Jen et al. Aug 2005 A1
20050192657 Colen et al. Sep 2005 A1
20050240254 Austin Oct 2005 A1
20050256562 Clerc et al. Nov 2005 A1
20060009833 Chobotov et al. Jan 2006 A1
20060030923 Gunderson Feb 2006 A1
20060041302 Malewicz Feb 2006 A1
20060074477 Berthiaume et al. Apr 2006 A1
20060189896 Davis et al. Aug 2006 A1
20060190069 Baker-Janis et al. Aug 2006 A1
20060229697 Gerdts et al. Oct 2006 A1
20060264904 Kerby et al. Nov 2006 A1
20060292300 Tan Dec 2006 A1
20070142894 Moore et al. Jun 2007 A1
20070208350 Gunderson Sep 2007 A1
20070282420 Gunderson Dec 2007 A1
20080021347 Jacobsen et al. Jan 2008 A1
20080021348 Jacobsen et al. Jan 2008 A1
20080021400 Jacobsen et al. Jan 2008 A1
20080021401 Jacobsen et al. Jan 2008 A1
20080021402 Jacobsen et al. Jan 2008 A1
20080021403 Jacobsen et al. Jan 2008 A1
20080021405 Jacobsen et al. Jan 2008 A1
20080021406 Jacobsen et al. Jan 2008 A1
20080021407 Jacobsen et al. Jan 2008 A1
20080021408 Jacobsen et al. Jan 2008 A1
20080077119 Snyder et al. Mar 2008 A1
20080135752 Motoi Jun 2008 A1
20080188920 Moberg et al. Aug 2008 A1
20090036967 Cummings Feb 2009 A1
20090048654 Chmura Feb 2009 A1
20090099637 Barthold et al. Apr 2009 A1
20090192584 Gerdts et al. Jul 2009 A1
20100256727 Gerdts et al. Oct 2010 A1
20130013047 Ramos et al. Jan 2013 A1
20140276412 Shumer Sep 2014 A1
20150057639 Storbeck et al. Feb 2015 A1
Foreign Referenced Citations (131)
Number Date Country
723040 Dec 1997 AU
733966 Apr 1998 AU
9712829 Jan 2000 BR
2266685 May 2006 CA
1230914 Oct 1999 CN
2539191 Mar 1976 DE
3621967 Jan 1988 DE
0045931 Feb 1982 EP
0069522 Jan 1983 EP
0087933 Sep 1983 EP
0111044 Jun 1984 EP
0181174 May 1986 EP
0377453 Jul 1990 EP
0521595 Jan 1993 EP
0565065 Oct 1993 EP
0608853 Aug 1994 EP
0676936 Oct 1995 EP
0684022 Nov 1995 EP
0775470 May 1997 EP
0778038 Jun 1997 EP
0778039 Jun 1997 EP
0778040 Jun 1997 EP
0790066 Aug 1997 EP
0807446 Nov 1997 EP
0812599 Dec 1997 EP
0865772 Sep 1998 EP
0865773 Sep 1998 EP
0917885 May 1999 EP
0937481 Aug 1999 EP
0820259 Feb 2003 EP
0935947 Dec 2004 EP
0934141 Nov 2005 EP
0385450 Mar 2007 EP
2214354 Aug 1989 GB
2257269 Jan 1993 GB
588522 Jan 1983 JP
60091858 May 1985 JP
61022752 Jan 1986 JP
62023361 Jan 1987 JP
62089470 Apr 1987 JP
63093516 Apr 1988 JP
63181774 Jul 1988 JP
3122850 Dec 1991 JP
4061840 Feb 1992 JP
4099963 Mar 1992 JP
4213069 Aug 1992 JP
4213070 Aug 1992 JP
4236965 Aug 1992 JP
5149969 Jun 1993 JP
5506806 Oct 1993 JP
5309519 Nov 1993 JP
5507857 Nov 1993 JP
6501179 Feb 1994 JP
6169996 Jun 1994 JP
6312313 Nov 1994 JP
728562 May 1995 JP
7124263 May 1995 JP
7505561 Jun 1995 JP
7037199 Jul 1995 JP
7185009 Jul 1995 JP
7275366 Oct 1995 JP
751067 Nov 1995 JP
8229888 Sep 1996 JP
8509141 Oct 1996 JP
9294813 Nov 1997 JP
10118193 May 1998 JP
10305039 Nov 1998 JP
10328191 Dec 1998 JP
11226131 Aug 1999 JP
11267224 Oct 1999 JP
2000197704 Aug 2000 JP
2000510722 Aug 2000 JP
2000511083 Aug 2000 JP
2001500808 Jan 2001 JP
2002529137 Sep 2002 JP
2002542901 Dec 2002 JP
2002543896 Dec 2002 JP
2003517893 Jun 2003 JP
3649604 Feb 2005 JP
2005534407 Nov 2005 JP
1529365 Dec 1989 SU
9002520 Mar 1990 WO
9113364 Sep 1991 WO
9204072 Mar 1992 WO
9207619 May 1992 WO
9304722 Mar 1993 WO
9311313 Jun 1993 WO
9524236 Sep 1995 WO
9619255 Jun 1996 WO
9710022 Mar 1997 WO
9717899 May 1997 WO
9725914 Jul 1997 WO
9743949 Nov 1997 WO
9744083 Nov 1997 WO
9744086 Nov 1997 WO
9810694 Mar 1998 WO
9904847 Feb 1999 WO
9911313 Mar 1999 WO
9949808 Oct 1999 WO
0018330 Apr 2000 WO
0023139 Apr 2000 WO
0027303 May 2000 WO
0027309 May 2000 WO
0030710 Jun 2000 WO
0048645 Aug 2000 WO
0057943 Oct 2000 WO
0066199 Nov 2000 WO
0067828 Nov 2000 WO
0067845 Nov 2000 WO
0071059 Nov 2000 WO
0072907 Dec 2000 WO
0128620 Apr 2001 WO
0136034 May 2001 WO
0145773 Jun 2001 WO
0145912 Jun 2001 WO
0176676 Oct 2001 WO
0193920 Dec 2001 WO
0213682 Feb 2002 WO
02056953 Jul 2002 WO
02062540 Aug 2002 WO
03004086 Jan 2003 WO
03008148 Jan 2003 WO
2004012804 Feb 2004 WO
2004047899 Jun 2004 WO
2004098692 Nov 2004 WO
2005020856 Mar 2005 WO
2005107644 Nov 2005 WO
2005112824 Dec 2005 WO
2006036472 Apr 2006 WO
2007084370 Jul 2007 WO
2012116337 Aug 2012 WO
Related Publications (1)
Number Date Country
20170135834 A1 May 2017 US
Provisional Applications (1)
Number Date Country
62255837 Nov 2015 US